Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M Hokland
Monocytes and Neutrophils as ‘Bad Guys’ for the Outcome of Interleukin-2 With and Without Histamine in Metastatic Renal Cell Carcinoma – Results From a Randomised Phase II Trial
British Journal of Cancer
Cancer Research
Oncology
Related publications
Two Randomised Phase II Trials of Subcutaneous Interleukin-2 and Histamine Dihydrochloride in Patients With Metastatic Renal Cell Carcinoma
British Journal of Cancer
Cancer Research
Oncology
Perioperative Immunomodulation With Interleukin-2 in Patients With Renal Cell Carcinoma: Results of a Controlled Phase II Trial
British Journal of Cancer
Cancer Research
Oncology
A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Recombinant Human Interleukin 6 in Metastatic Renal Cell Cancer: A Phase II Trial
British Journal of Cancer
Cancer Research
Oncology
A Randomised Dose Escalation Study of Subcutaneous Interleukin 2 With and Without Levamisole in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma
British Journal of Cancer
Cancer Research
Oncology
Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma
Urology
Urology
Sorafenib With Interleukin-2 vs Sorafenib Alone in Metastatic Renal Cell Carcinoma: The ROSORC Trial
British Journal of Cancer
Cancer Research
Oncology
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Oncologist
Cancer Research
Medicine
Oncology
Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
